Table 3 Multivariate analysis of... | American Society of Hematology

Table 3

Multivariate analysis of molecular and clinical factors

Factor	EFS		OS
Factor	Hazard ratio (95% CI)	P	Hazard ratio (95% CI)	P
FLT3-ITD	3.67 (1.43-9.42)	.007	2.73 (0.82-9.15)	NS
NPM1 mutation	0.68 (0.18-2.61)	NS	0.76 (0.15-3.82)	NS
High ERG expression	1.28 (0.73-2.26)	NS	0.94 (0.48-1.84)	NS
High BAALC expression	1.90 (1.04-3.46)	.037	1.55 (0.78-3.06)	NS
WBC count higher than 100 × 10⁹/L	1.02 (0.50-2.08)	NS	0.84 (0.33-2.12)	NS
Age, y	1.00 (0.94-1.05)	NS	1.01 (0.95-1.08)	NS
Cytogenetic high-risk group*	1.73 (0.95-3.15)	NS	2.52 (1.27-4.99)	.008
Good response to induction therapy†	0.38 (0.20-0.71)	.002	0.61 (0.28-1.32)	NS
SCT in CR1‡	0.28 (0.13-0.59)	.001	0.49 (0.22-1.11)	NS

Factor	EFS		OS
Factor	Hazard ratio (95% CI)	P	Hazard ratio (95% CI)	P
FLT3-ITD	3.67 (1.43-9.42)	.007	2.73 (0.82-9.15)	NS
NPM1 mutation	0.68 (0.18-2.61)	NS	0.76 (0.15-3.82)	NS
High ERG expression	1.28 (0.73-2.26)	NS	0.94 (0.48-1.84)	NS
High BAALC expression	1.90 (1.04-3.46)	.037	1.55 (0.78-3.06)	NS
WBC count higher than 100 × 10⁹/L	1.02 (0.50-2.08)	NS	0.84 (0.33-2.12)	NS
Age, y	1.00 (0.94-1.05)	NS	1.01 (0.95-1.08)	NS
Cytogenetic high-risk group*	1.73 (0.95-3.15)	NS	2.52 (1.27-4.99)	.008
Good response to induction therapy†	0.38 (0.20-0.71)	.002	0.61 (0.28-1.32)	NS
SCT in CR1‡	0.28 (0.13-0.59)	.001	0.49 (0.22-1.11)	NS

Cytogenetic high-risk group defined as −7, 3q12q26, or mixed lineage leukemia rearrangement other than t(9;11).

Good response defined as < 5% BM blasts after induction therapy.

SCT treated as a time-dependent variable with months as time unit.